MedPath

Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use

Not Applicable
Recruiting
Conditions
Pregnancy
Cannabis
Interventions
Behavioral: LPA + Fitbit Intervention
Registration Number
NCT05528380
Lead Sponsor
Butler Hospital
Brief Summary

This study will recruit 20 women who are high risk for prenatal cannabis use for a 12-week program of using the tracker and receiving a Lifestyle Physical Activity program. The primary outcomes will be self reported percent days of cannabis use and physical activity. Secondary outcomes include self -reported measures of depression and anxiety symptoms, adaptive coping, and self-efficacy for cannabis abstinence.

Detailed Description

This study will recruit 20 women in an open trial who are high risk for prenatal cannabis use for a 12-week program of using a Fitbit activity tracker and receiving a Lifestyle Physical Activity program. The primary outcomes will be self reported percent days of cannabis use and physical activity. Secondary outcomes include self -reported measures of depression and anxiety symptoms, adaptive coping, and self-efficacy for cannabis abstinence. The investigators will clinically monitor all participants in the study for safety and clinical deterioration, and measure a variety of symptom outcomes over the course of the intervention period during pregnancy, as well as at a postpartum follow-up.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
50
Inclusion Criteria
  • Women aged 18+
  • 12-25 weeks gestation with a healthy singleton pregnancy
  • Medically cleared for moderate physical activity
  • Self-report of cannabis use at least once/week in the 3 months prior to the pregnancy desire to not engage in prenatal cannabis use
  • Elevated depression (EPDS>=7) or anxiety (GAD7>=5)
  • English-speaking
  • Owns a smartphone to enable use of the Fitbit app
  • Current physical activity does not meet health recommendations (150 min/week mod intensity activity)
  • Expresses interest in reducing or discontinuing cannabis use
Exclusion Criteria
  • Current DSM-5 diagnosis of moderate/severe substance use disorder other than CUD or nicotine use disorder
  • Use of illicit substances in the last 3 months (other than cannabis)
  • Acute psychotic symptoms
  • Current or recent suicidality or homicidally
  • Current anorexia or bulimia
  • Cognitive impairment
  • Physical or medical problems that would not allow safe participation in moderate intensity PA (i.e., not medical cleared by Ob/Gyn)
  • Has a plan to relocate away from the area during study period
  • Recently started new mental health or substance use treatment within past 4 weeks.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Open Trial InterventionLPA + Fitbit InterventionParticipants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
Primary Outcome Measures
NameTimeMethod
Activity Minutes/DayBaseline to 12-week endpoint

objectively-measured

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 3Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 3: age of onset

Timeline Follow-back (TLFB)Baseline to 12-week endpoint

Interviewer-administered assessment of use of cannabis, alcohol, tobacco, and other drugs

Steps/dayBaseline to 12-week endpoint

objectively-measured

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 2Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 2: frequency

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 5Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 5: Concentrate quantity

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 6Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 6: Edibles quantity

Urine Toxicology ScreenBaseline to 12-week endpoint

Objective screening for use of cannabis via measurement of THC in urine samples

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 1Baseline to 12-week endpoint

Self-reported cannabis use questionnaire -factor 1: daily sessions

International Physical Activity QuestionnaireBaseline to 12-week endpoint

self-report measure of physical activity including minutes/week spent walking, engaging in moderate physical activity, and engaging in vigorous physical activity

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 4Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 4: Marijuana quantity

Secondary Outcome Measures
NameTimeMethod
Generalized Anxiety Disorder -7Baseline to 12-week endpoint

Self-report measure of anxiety severity; scores range from 0-21, with higher scoring indicating more anxiety

Brief COPEBaseline to 12-week endpoint

Self-report measure of of use of coping strategies; includes 14 2-item scales, each ranging form 2-8. Higher scores indicate increased utilization of a coping strategy.

Marijuana Self-Efficacy QuestionnaireBaseline to 12-week endpoint

Self-report measure of efficacy for cannabis abstinence; Scores range from 0-100, with higher scores indicating greater use of strategies to reduce marijuana consumption.

Edinburgh Postnatal Depression ScreenBaseline to 12-week endpoint

Self-report measure of depression severity; scores range from 0-30, with higher scores indicating higher depression

Trial Locations

Locations (1)

Butler Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath